RxDoctor Payments Data

Arcot Dwarakanathan

Endocrinology, Diabetes & Metabolism · Olympia Fields, ILNPI 1508880287

Payments from drug & device makers

$698in general payments, 2019–2025

Across 15 payments — averaging $46.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$500
  • Abbott$70
  • Sanofi-aventis U.S. LLC$47
  • Mannkind Corporation$20
  • Valeritas, Inc.$18
  • Shire North American Group Inc$17
  • plus $26 from 2 others

What the payments were for

  • Speaking & faculty fees$50072%
  • Food & beverage$16624%
  • Education$325%

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$698 in reported general payments places this provider in the 45th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.

See all endocrinology, diabetes & metabolism providers in Illinois

Medicare billing

Part B allowed, 2024
$65,297
Medicare patients
206
Services billed
515

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide349$608,461
JardianceEmpagliflozin127$198,333
Tresiba Flextouch U-200Insulin Degludec81$102,106
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog48$64,056
TrulicityDulaglutide31$49,347
JanuviaSitagliptin Phosphate34$48,195
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog55$45,436
FarxigaDapagliflozin Propanediol29$33,770
Tresiba Flextouch U-100Insulin Degludec39$23,455
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog29$23,386
TradjentaLinagliptin14$21,667
Fiasp FlextouchInsulin Aspart (Niacinamide)16$21,421
Cinacalcet Hcl20$20,930
MounjaroTirzepatide13$18,188
Lantus SolostarInsulin Glargine,hum.Rec.Anlog59$14,512

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$15$608,461349 claims
Lilly USA, LLCTrulicity, Mounjaro$12$67,53544 claims
AstraZenecaFarxiga$500$33,77029 claims
Sanofi-aventis U.S. LLCLantus$47$1,10811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.

Other endocrinology, diabetes & metabolism in Olympia Fields

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →